FLUO.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 06:54):

Stats
Today's Volume	6 227.00
Average Volume	9 433.00
Market Cap	658.70M
EPS	SEK0 ( 2024-02-28 )
Next earnings date	( SEK0 ) 2024-05-28
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-10.67
ATR14	SEK0.987 (1.83%)

FluoGuide A/S Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

FluoGuide A/S Financials

Annual	2023
Revenue:	SEK423 000
Gross Profit:	SEK423 000 (100.00 %)
EPS:	SEK-3.22

FY	2023
Revenue:	SEK423 000
Gross Profit:	SEK423 000 (100.00 %)
EPS:	SEK-3.22

FY	2022
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-2.33

FY	2021
Revenue:	SEK0.00
Gross Profit:	SEK0.00 (0.00 %)
EPS:	SEK-2.15

Financial Reports:

No articles found.

FluoGuide A/S

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.